Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.
Michael J. Morris, MD, medical oncologist, clinical director of Genitourinary Medical Oncology Service, and Prostate Cancer Section Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the promising future of prostate-specific membrane antigen (PSMA)–targeted PET imaging in prostate cancer.
PSMA-targeted PET imaging has become one of the most promising molecular imaging modalities in prostate cancer, says Morris. Based on a multitude of data that continues to be collected on an international level, investigators now believe that PSMA-targeted PET imaging is superior to standard imaging modalities that are commonly used in the United States, such as cross-sectional anatomic imaging and skeletal scintigraphy, adds Morris.
However, to date, PSMA-targeted PET imaging has not yet received approval in the United States, says Morris. However, the phase 3 CONDOR study was designed to accumulate data for the regulatory approval of F-DCFPyL, a PSMA tracer.
CONDOR is 1 of 2 trials that is intended to provide the FDA with the necessary evidence needed to obtain regulatory approval of this agent for PSMA-targeted PET imaging in prostate cancer, concludes Morris.